← FDA DRUG APPROVALS
FDA ANDA · ANDA075502
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
Sponsor: FOUGERA PHARMS
APPLICATION
ANDA075502
TYPE
ANDA
ORIGINAL APPROVAL
2001-06-05
LATEST ACTION
2020-07-06
ROUTE
TOPICAL
DOSAGE FORM
CREAM
MARKETING STATUS
Prescription
Products
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATEPrescription
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE, CLOTRIMAZOLE 1% · CREAM · TOPICAL
Approval history
2020-07-06Labeling · Supplement 18 · standardAP
2020-07-06Labeling · Supplement 19 · standardAP
2015-09-11Labeling · Supplement 14 · standardAP
2015-09-11Labeling · Supplement 15 · standardAP
2003-06-26Labeling · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.